financetom
Business
financetom
/
Business
/
Hindenburg Research Targets Equinix In New Short Report Claiming Data Center Firm Is Selling 'AI Pipe Dream'
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hindenburg Research Targets Equinix In New Short Report Claiming Data Center Firm Is Selling 'AI Pipe Dream'
Mar 20, 2024 9:14 AM

Short seller Hindenburg research has a new company in its crosshairs.

What To Know: Hindenburg has targeted data center firm Equinix Inc ( EQIX ) in a new short report published on Wednesday and announced a new short position against the company.

The short seller claims Equinix ( EQIX ) inflated its profitability metrics and pitched investors an “AI pipe dream,” while insiders backed out of the stock.

Equinix ( EQIX ) shares fell as much as 7% in early trading Wednesday before bouncing back. The stock was down approximately 4.5% at the time of writing.

A spokesperson for Equinix ( EQIX ) told Benzinga the company is “investigating the claims” and “will respond in due course.”

From Last Week: Are Palantir CEO’s Cocaine Comments A ‘Projection?’ Legendary Short Sellers Clap Back At Critiques, Flag Insider Trade Data

The Details: Hindenburg alleged that Equinix ( EQIX ) has used accounting tricks to boost its adjusted funds from operations (AFFO). The short seller claims the company reclassified its capital expenditures reporting to make it appear more profitable than it is.

“Our investigation found that Equinix ( EQIX ) bases its executive bonus compensation on the company's AFFO metric (ii) then manipulates its accounting for maintenance CapEx to overstate this AFFO figure, resulting in the illusion of vastly higher AFFO, higher executive bonus compensation and an inflated stock price,” the short seller said.

Hindenburg believes the alleged capital expenditures manipulation has boosted Equinix’s AFFO by about $3 billion cumulatively since 2015. Meanwhile, insiders have cash out more than $327 million in company stock since 2019, the short seller said.

The firm’s investigation involved 37 former employees of Equinix ( EQIX ), as well as several industry experts and competitors. Equinix ( EQIX ) has over 10,000 customers, ranging from small businesses to large cloud providers like Amazon, Microsoft and Google.

Read Next: Fed Interest Rate Cut Bets Skate On Thin Ice, Markets On Edge: FOMC Meeting Preview

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
3M Insider Sold Shares Worth $700,608, According to a Recent SEC Filing
3M Insider Sold Shares Worth $700,608, According to a Recent SEC Filing
Aug 8, 2024
09:43 AM EDT, 08/08/2024 (MT Newswires) -- Michael F Roman, Director, Chairman of the Board, on August 07, 2024, sold 5,675 shares in 3M ( MMM ) for $700,608. Following the Form 4 filing with the SEC, Roman has control over a total of 174,036 shares of the company, with 174,036 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/66740/000112760224021839/xslF345X03/form4.xml Price: 123.00, Change:...
Hanesbrands Q2 Adjusted Earnings Rise, Sales Decline; 2024 Outlook Slashed
Hanesbrands Q2 Adjusted Earnings Rise, Sales Decline; 2024 Outlook Slashed
Aug 8, 2024
09:43 AM EDT, 08/08/2024 (MT Newswires) -- Hanesbrands ( HBI ) reported Q2 adjusted earnings of $0.15 per diluted share, up from $0.02 a year earlier. Analysts polled by Capital IQ expected $0.10. Net sales for the quarter ended June 29 were $995.4 million, compared with $1.04 billion a year earlier. Four analysts surveyed by Capital IQ expected $1.35 billion....
Avadel Pharmaceuticals Narrows Q2 Net Loss as Product Revenue Climbs
Avadel Pharmaceuticals Narrows Q2 Net Loss as Product Revenue Climbs
Aug 8, 2024
09:42 AM EDT, 08/08/2024 (MT Newswires) -- Avadel Pharmaceuticals ( AVDL ) gained nearly 1% in early Thursday trading after the drug maker reported a Q2 net loss of $0.14 per diluted share, compared with a loss of $0.83 a year earlier. Analysts polled by Capital IQ expected a $0.13 loss. Net product revenue for the quarter ended June 30...
LifeStance Health Q2 Net Loss Narrows, Revenue Rises
LifeStance Health Q2 Net Loss Narrows, Revenue Rises
Aug 8, 2024
09:41 AM EDT, 08/08/2024 (MT Newswires) -- LifeStance Health ( LFST ) reported a Q2 net loss Thursday of $0.06 per diluted share, narrower than a per-share loss of $0.13 a year earlier. Analysts polled by Capital IQ expected a per-share loss of $0.06. Revenue for the quarter ended June 30 was $312.3 million, up from $259.6 million a year...
Copyright 2023-2026 - www.financetom.com All Rights Reserved